Furthermore, the nuclear receptor superfamily of ligand-activated transcription factors includes the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists which can treat type 2 diabetes and obesity-related insulin resistance [3]. This evidence concerns the gene PPARG and Insulin resistance.